DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Study to Demonstrate the Analgesic Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Addition to Pregabalin Compared to Pregabalin Alone in Opioid-naïve Subjects Treated With Pregabalin Suffering From Moderate to Severe Pain Due to Diabetic Polyneuropathy

Information source: Mundipharma Research GmbH & Co KG
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Moderate to Severe Pain Due to Diabetic Polyneuropathy

Intervention: Oxycodone Naloxone (Drug); Placebo tablets (Drug)

Phase: Phase 2

Status: Recruiting

Sponsored by: Mundipharma Research GmbH & Co KG

Summary

To show superior analgesic efficacy of OXN PR in addition to a patient's current dose of pregabalin compared to pregabalin alone.

Clinical Details

Official title: An Exploratory, Randomised, Double-blind, Single-dummy, Placebo Controlled, Parallel Group Study to Demonstrate the Analgesic Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Addition to Pregabalin Compared to Pregabalin Alone in Opioid-nave Subjects Treated With Pregabalin Suffering From Moderate to Severe Pain Due to Diabetic Polyneuropathy

Study design: Basic Science, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study

Primary outcome: To show superior analgesic efficacy of OXN PR in addition to a patient's current dose of pregabalin compared to pregabalin alone

Detailed description: Study OXN2502 is a pilot, exploratory, randomised, placebo-controlled, double-blind, single-dummy, parallel group study to assess efficacy and safety of OXN PR in addition to a patient's current dose of pregabalin compared to pregabalin alone in opioid-naïve subjects treated with pregabalin suffering from moderate to severe pain due to diabetic polyneuropathy.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion criteria:

- Moderate to severe pain due diabetic polyneuropathy

- Opioid-naive subjects

Exclusion criteria:

- Females who are pregnant or lactating

- Subjects with evidence of significant structural abnormalities of the

gastrointestinal tract

- Subjects with evidence of impaired liver/kidney function upon entry into the study

Locations and Contacts

Dr Oliver Emrich, Ludwigshafen 67069, Germany; Recruiting
Margaret Wilson, Email: info@contact-clinical-trials.com
Jill Kiteley, Email: info@contact-clinical-trials.com
Additional Information

Starting date: July 2009
Ending date: May 2010
Last updated: August 11, 2009

Page last updated: October 19, 2009

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012